InsiderClue
Stocks · Health care · Pharmaceutical Preparations

ADIAL PHARMACEUTICALS, INC.

ADIL Clue Score41
United States Fiscal year ends December CIK 0001513525
$3.90 -1.76% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.90 +5.12% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 27 Jul 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2017Operating income−1.0Net income−1.1Fiscal year 2018Operating income−7.0Net income−11.6Fiscal year 2019Operating income−8.2Net income−8.6Fiscal year 2020Operating income−10.9Net income−10.9Fiscal year 2021Operating income−19.3Net income−19.4EPS, diluted−1.04Fiscal year 2022Operating income−10.9Net income−12.7EPS, diluted−12.71Fiscal year 2023Operating income−6.9Net income−5.1EPS, diluted−3.60Fiscal year 2024Operating income−8.3Net income−13.2EPS, diluted−68.01Fiscal year 2025Operating income−7.8Net income−8.0EPS, diluted−11.93
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −1.0 −7.0 −8.2 −10.9 −19.3 −10.9 −6.9 −8.3 −7.8
Net income −1.1 −11.6 −8.6 −10.9 −19.4 −12.7 −5.1 −13.2 −8.0
Growth
EPS, diluted n/a n/a n/a n/a −1.04 −12.71 −3.60 −68.01 −11.93

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−0.5Fiscal year 2018Operating cash flow−2.5Fiscal year 2019Operating cash flow−6.3Fiscal year 2020Operating cash flow−7.6Fiscal year 2021Operating cash flow−11.9Capital expenditure−0.1Free cash flow−12.0Fiscal year 2022Operating cash flow−11.2Fiscal year 2023Operating cash flow−6.8Buybacks−0.0Fiscal year 2024Operating cash flow−6.9Fiscal year 2025Operating cash flow−6.5
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −0.5 −2.5 −6.3 −7.6 −11.9 −11.2 −6.8 −6.9 −6.5
Capital expenditure n/a n/a n/a n/a −0.1 n/a n/a n/a n/a
Free cash flow n/a n/a n/a n/a −12.0 n/a n/a n/a n/a
Growth
Buybacks n/a n/a n/a n/a n/a n/a −0.0 n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2017Cash0.0Shareholders’ equity−1.0Fiscal year 2018Cash3.9Shareholders’ equity4.4Fiscal year 2019Cash6.8Shareholders’ equity7.1Fiscal year 2020Cash4.4Shareholders’ equity4.0Fiscal year 2021Cash6.1Shareholders’ equity3.5Fiscal year 2022Cash4.0Shareholders’ equity3.3Fiscal year 2023Cash2.8Shareholders’ equity4.1Fiscal year 2024Cash3.8Shareholders’ equity4.1Fiscal year 2025Cash5.9Shareholders’ equity5.3
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 0.0 3.9 6.8 4.4 6.1 4.0 2.8 3.8 5.9
Shareholders’ equity −1.0 4.4 7.1 4.0 3.5 3.3 4.1 4.1 5.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −261.9% −120.3% −273.3% −553.7% −388.6% −125.5% −324.4% −151.2%
−3,298.4% −247.5% −111.9% −198.4% −259.8% −222.1% −108.2% −261.6% −119.5%
Balance and payout
n/a n/a n/a 27.4% 53.1% 42.8% 13.8% 19.3% 20.9%